153 related articles for article (PubMed ID: 21917434)
21. Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents.
Sarno G; Räber L; Onuma Y; Garg S; Brugaletta S; van Domburg RT; Pilgrim T; Pfäffli N; Wenaweser P; Windecker S; Serruys P
Am J Cardiol; 2011 Jul; 108(2):195-201. PubMed ID: 21529741
[TBL] [Abstract][Full Text] [Related]
22. Impact of admission creatinine level on clinical outcomes of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stent implantation.
Zhang Q; Zhang RY; Shen J; Zhang JS; Hu J; Yang ZK; Zhang X; Zheng AF; Shen WF
Chin Med J (Engl); 2008 Dec; 121(23):2379-83. PubMed ID: 19102952
[TBL] [Abstract][Full Text] [Related]
23. Can "Hybrid stent implantation" improve long-term safety without adversely affecting efficacy when treating multilesion coronary artery disease in the drug-eluting stent era?
Zhang D; Xu B; Dou KF; Yang YJ; Chen JL; Qiao SB; Wang Y; Li JJ; Qin XW; Yao M; Liu HB; Wu YJ; Chen J; Yuan JQ; You SJ; Li W; Gao RL
Chin Med J (Engl); 2013; 126(9):1612-7. PubMed ID: 23652038
[TBL] [Abstract][Full Text] [Related]
24. Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry.
Yan BP; Ajani AE; New G; Duffy SJ; Farouque O; Shaw J; Sebastian M; Lew R; Brennan A; Andrianopoulos N; Reid C; Clark DJ;
Int J Cardiol; 2008 Nov; 130(3):374-9. PubMed ID: 18706719
[TBL] [Abstract][Full Text] [Related]
25. Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus-eluting stent: 1- and 2-year data from the E-Five Registry.
Rothman MT; Jain AK;
Catheter Cardiovasc Interv; 2012 Nov; 80(6):885-92. PubMed ID: 22517785
[TBL] [Abstract][Full Text] [Related]
26. Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year.
Stolker JM; Cohen DJ; Kennedy KF; Pencina MJ; Lindsey JB; Mauri L; Cutlip DE; Kleiman NS;
Circ Cardiovasc Interv; 2012 Dec; 5(6):772-82. PubMed ID: 23093553
[TBL] [Abstract][Full Text] [Related]
27. Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry.
Jensen JK; Jensen LO; Terkelsen CJ; Lassen JF; Tilsted HH; Hansen KN; Maeng M; Thuesen L; Thayssen P
Catheter Cardiovasc Interv; 2013 Feb; 81(2):260-5. PubMed ID: 22511512
[TBL] [Abstract][Full Text] [Related]
28. Impact of gender on clinical outcomes after mTOR-inhibitor drug-eluting stent implantation in patients with first manifestation of ischaemic heart disease.
Niccoli G; Sgueglia GA; Cosentino N; Piro M; Toma A; Cataneo L; Fracassi F; Porto I; Leone AM; Burzotta F; Trani C; Crea F
Eur J Prev Cardiol; 2012 Oct; 19(5):914-26. PubMed ID: 21840968
[TBL] [Abstract][Full Text] [Related]
29. Impact of gender on long-term mortality in patients with unprotected left main disease: The Milan and New-Tokyo (MITO) Registry.
Takagi K; Chieffo A; Shannon J; Naganuma T; Tahara S; Fujino Y; Latib A; Montorfano M; Carlino M; Kawamoto H; Nakamura S; Colombo A
Cardiovasc Revasc Med; 2016 Sep; 17(6):369-74. PubMed ID: 27460302
[TBL] [Abstract][Full Text] [Related]
30. Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients.
Du R; Zhang RY; Zhu ZB; Zhang Q; Hu J; Yang ZK; Yan ZJ; Lv AK; Ding FH; Zhang JS; Shen WF
Coron Artery Dis; 2010 May; 21(3):175-81. PubMed ID: 20305549
[TBL] [Abstract][Full Text] [Related]
31. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of first generation versus new-generation drug-eluting stents in three-vessel coronary artery disease.
Yoshizaki T; Naganuma T; Kobayashi T; Horikoshi T; Onishi H; Kawamoto H; Nakamura S; Nakamura S
Cardiovasc Revasc Med; 2017; 18(7):492-496. PubMed ID: 28546033
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
Qasim A; Cosgrave J; Latib A; Colombo A
Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
[TBL] [Abstract][Full Text] [Related]
34. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials.
Baber U; Giustino G; Sartori S; Aquino M; Stefanini GG; Steg PG; Windecker S; Leon MB; Wijns W; Serruys PW; Valgimigli M; Stone GW; Dangas GD; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari D; Von Birgelen C; Mastoris I; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R
JACC Cardiovasc Interv; 2016 Jan; 9(1):28-38. PubMed ID: 26762908
[TBL] [Abstract][Full Text] [Related]
35. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy).
Maeng M; Jensen LO; Tilsted HH; Kaltoft A; Kelbaek H; Abildgaard U; Villadsen A; Aarøe J; Thayssen P; Krusell LR; Christiansen EH; Bøtker HE; Kristensen SD; Ravkilde J; Madsen M; Sørensen HT; Rasmussen K; Thuesen L; Lassen JF
Am J Cardiol; 2011 Nov; 108(9):1232-7. PubMed ID: 21864817
[TBL] [Abstract][Full Text] [Related]
36. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
Tolerico PH; Cohen DJ; Kleiman NS; Berger PB; Brilakis ES; Piana RN; Shammo S; Keyes MJ; Kennedy KF; Massaro JM; Saucedo JF;
Catheter Cardiovasc Interv; 2012 Dec; 80(7):1127-36. PubMed ID: 22431166
[TBL] [Abstract][Full Text] [Related]
37. Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.
Almalla M; Schröder JW; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2013 Mar; 24(2):165-70. PubMed ID: 23242011
[TBL] [Abstract][Full Text] [Related]
38. Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.
Takagi K; Ielasi A; Shannon J; Latib A; Godino C; Davidavicius G; Mussardo M; Ferrarello S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A
Circ Cardiovasc Interv; 2012 Aug; 5(4):491-8. PubMed ID: 22851528
[TBL] [Abstract][Full Text] [Related]
39. Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry.
Akin I; Bufe A; Eckardt L; Reinecke H; Richardt G; Kuck KH; Senges J; Schneider S; Nienaber CA;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):50-7. PubMed ID: 20578192
[TBL] [Abstract][Full Text] [Related]
40. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology.
Talarico GP; Burzotta F; Trani C; Tommasino A; Niccoli G; Porto I; Leone AM; Mongiardo R; Schiavoni G; Crea F
Catheter Cardiovasc Interv; 2013 Feb; 81(2):268-73. PubMed ID: 22639426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
